Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy
02:03pm, Friday, 01'st Sep 2023
Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully concluded its Phase III clinical trial for recurrent
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
09:55am, Tuesday, 08'th Aug 2023
Seres Therapeutics (MCRB) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to loss of $0.70 per share a year ago.
Best Penny Stocks To Buy? 5 With Big News This Week
11:16am, Wednesday, 07'th Jun 2023
Are you searching for some of the best penny stocks to buy now? I'm sure that if you're reading this article, that's something at the top of your mind.
Seres Therapeutics to Present at Jefferies Healthcare Conference
07:00am, Friday, 02'nd Jun 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres T
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
09:57am, Tuesday, 09'th May 2023
Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 per share a year ago.
Seres Gets FDA Approval And The Share Price Goes Down!
10:29am, Wednesday, 03'rd May 2023
Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weird. On April 26, Seres achieved FDA approval for VO
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
09:45am, Thursday, 20'th Apr 2023
Growth stocks fell across the board in 2022. This broad pullback may have created some tremendous buying opportunities.
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
06:51am, Friday, 14'th Apr 2023
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
05:21am, Wednesday, 22'nd Mar 2023
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript
02:05pm, Tuesday, 07'th Mar 2023
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric Shaff - President, CEO & Director Teresa Young - EV
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Tuesday, 07'th Mar 2023
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics: FDA Approval Straight Ahead
02:42pm, Monday, 06'th Feb 2023
Today, we take a look at microbiome therapeutic developer Seres Therapeutics, Inc. Seres Therapeutics appears headed to its first FDA approval and has a strategic partnership with Nestlé S.A. around
The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid
02:34am, Sunday, 05'th Feb 2023
April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of
Charter Communications, Braze And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
12:53pm, Wednesday, 14'th Dec 2022 Benzinga
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
iQIYI, Inc. (NASDAQ: IQ) shares dipped 14.1% to $3.31 in pr
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
11:30am, Wednesday, 14'th Dec 2022 Benzinga
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.
Crown ElectroKinetic
